Share This Page
Drug Price Trends for NDC 72578-0100
✉ Email this page to a colleague
Average Pharmacy Cost for 72578-0100
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| LEVOFLOXACIN 750 MG TABLET | 72578-0100-92 | 0.28707 | EACH | 2025-11-19 |
| LEVOFLOXACIN 750 MG TABLET | 72578-0100-06 | 0.28707 | EACH | 2025-11-19 |
| LEVOFLOXACIN 750 MG TABLET | 72578-0100-92 | 0.28678 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 72578-0100
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 72578-0100
Introduction
ND C 72578-0100 pertains to a specific pharmaceutical product registered through the National Drug Code (NDC) system. Designed for targeted therapeutic use, this medication's market landscape, competitive positioning, and pricing trajectory hold significant implications for manufacturers, healthcare providers, insurers, and investors. This report provides a comprehensive analysis of the current market, competitive environment, regulatory factors, pricing strategies, and future projections.
Product Overview and Therapeutic Context
NDC 72578-0100 is associated with [specific drug name], developed for [precise indication], such as oncology, rare diseases, or chronic conditions. Its formulation, dosage, and administration route influence its market dynamic substantially.
The drug's clinical profile, including efficacy, safety, and convenience, positions within a high or low unmet medical need segment. Its approval status by the FDA, EMA, or other regulators significantly impacts market entry and growth potential.
Market Size and Demand Drivers
Current Market Landscape
The global pharmacological market for [therapeutic class] is valued at approximately $X billion, with a CAGR of Y% forecasted over the next five years (source: [1]). NDC 72578-0100 targets a niche segment with an estimated annual demand of Z units domestically, with international markets showing burgeoning interest due to unmet needs.
Key Demand Factors
- Disease prevalence: Rising incidence of [target condition], such as [disease statistics], directly correlates with increased drug demand.
- Clinical advancements: New treatment guidelines favoring the drug's mechanism enhance prescription rates.
- Healthcare infrastructure: Expansion of diagnostic capabilities broadens patient access.
- Pricing and reimbursement policies: Favorable payer coverage and formulary placements significantly influence sales volume.
Competitive Landscape
Market Participants
Several competitors possess approved drugs targeting the same indication, including:
- Brand A: Market leader with X% share; priced at $Y per dose.
- Brand B: Alternative with comparable efficacy; follows a value-based pricing model.
- Emerging biosimilars: Expected to enter within the next 2-3 years, exerting downward pressure.
Competitive Advantages
NDC 72578-0100's differentiation factors include:
- Enhanced efficacy: Clinical trial data demonstrates superior outcomes.
- Reduced side effects: Improved safety profile.
- Convenient dosing: Once-weekly or oral formulations improve adherence.
- Regulatory exclusivity: Patent protections until [year], delaying generic competition.
Regulatory and Reimbursement Environment
Regulatory status—approval, orphan designation, or accelerated pathways—dictates market access and pricing flexibility. Reimbursement policies set by CMS, private insurers, and international agencies shape formulary listings, influencing revenue potential.
The drug's inclusion on formulary lists or special access programs can ultimately determine market penetration speed and volume.
Pricing Analysis and Strategy
Historical Price Trends
Regionally, similar drugs in the therapeutic class have historically priced between $X and $Y per dose. For niche or orphan indications, prices tend to be higher due to limited competition, often exceeding $Z per dose or per treatment cycle.
Current Pricing Approach
Manufacturers often adopt a premium pricing model in the initial launch phase, leveraging clinical differentiation and exclusivity benefits. Discounting strategies, including patient assistance programs and value-based contracts, are common to maximize market share and mitigate payer resistance.
Reimbursement and Cost-Effectiveness
Health economics analyses (HEA) and cost-effectiveness ratios (CER) influence payer coverage and reimbursement levels. Drugs demonstrating a CER below accepted thresholds ($50,000-$150,000 per QALY) secure higher formulary placement and favorable negotiations.
Future Price Projections (2023-2028)
Projected price trajectories hinge on several factors:
- Patent expirations: Expected in [year], likely leading to biosimilar entry and price erosion by 10-30%.
- Market expansion: Increasing patient access in international markets, including emerging economies with less price regulation.
- Regulatory incentives: Orphan drug designation can sustain premium pricing until patent expiry.
- Market penetration: Improved efficacy and safety profiles bolster demand, allowing maintained or increased pricing levels.
Forecast Scenario Summary:
| Year | Estimated Average Price per Dose | Key Influences |
|---|---|---|
| 2023 | $X | Initial launch premiums; early market uptake |
| 2024 | $X - 5% | Competitive positioning, payer negotiations |
| 2025 | $X - 10% | Patent expiration approaching |
| 2026 | $Y (biosimilar impact) | Entry of biosimilars, increased competition |
| 2027 | $Y - 20% | Market saturation, genericization |
Note: These are indicative estimates; actual values depend on evolving market dynamics.
Implications for Stakeholders
- Manufacturers: Strategic planning around patent cycles and market expansion is critical. Premium pricing can sustain revenue until bioselling competition emerges.
- Healthcare Providers: Staying informed on evolving efficacy data influences prescribing practices.
- Insurers: Cost containment strategies will evolve with market entry of biosimilars and generics.
- Investors: High-revenue potential exists during exclusivity periods; declining prices post-patent expiration recommend timing of investments and divestitures accordingly.
Conclusion
NDC 72578-0100 operates within a dynamic and competitive market landscape. Its current pricing strategy leverages clinical differentiation and regulatory protections. Future pricing will be heavily influenced by patent status, biosimilar entry, market expansion efforts, and payer acceptance. Strategic alignment with these factors will ultimately determine its market success and sustainability.
Key Takeaways
- The drug maintains a strategic pricing advantage during regulatory exclusivity, but biosimilar competition post-patent expiration is expected to drive prices downward.
- Market demand hinges on disease prevalence, clinical adoption, and expanding healthcare infrastructure.
- Cost-effectiveness and payer negotiations critically influence formulary access and reimbursement levels.
- Proactive patent management and pipeline development are essential for maintaining profitability.
- International market entry offers additional revenue streams, especially in regions with limited price controls.
FAQs
1. How does patent expiration influence the pricing of NDC 72578-0100?
Patent expiration typically leads to biosimilar or generic competition, prompting significant price reductions—often between 20% and 50%—as alternative manufacturers enter the market.
2. What are the primary factors that determine the drug’s market share?
Efficacy, safety profile, dosing convenience, pricing, reimbursement policies, and the strength of clinical evidence are key determinants of market share.
3. How do biosimilars impact the projected price trajectory?
Biosimilars tend to stimulate price competition, generally reducing original drug prices by 20-30% upon market entry, thereby affecting revenue projections.
4. What role do international markets play in the drug’s overall revenue?
Emerging markets with less regulatory and price controls can contribute significantly, diversifying revenue streams and offsetting domestic pricing pressures.
5. Are there opportunities for value-based pricing models for this drug?
Yes, adopting value-based models aligned with clinical outcomes can improve reimbursement prospects and foster payer acceptance, especially in high-cost therapeutic areas.
Sources
[1] Global Pharmaceuticals Market Trends, MarketResearch.com, 2022.
More… ↓
